Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic and molecular remissions. However, approximately 15–20% fail to obtain optimal responses ac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Principais autores: Massimino, Michele, Stella, Stefania, Tirrò, Elena, Romano, Chiara, Pennisi, Maria Stella, Puma, Adriana, Manzella, Livia, Zanghì, Antonino, Stagno, Fabio, Di Raimondo, Francesco, Vigneri, Paolo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817805/
https://ncbi.nlm.nih.gov/pubmed/29455672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-018-0805-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados